These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28477683)

  • 21. Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
    Antonelli T; Tomasini MC; Castellazzi M; Sola P; Tamborino C; Ferraro D; Ferraro L; Granieri E
    Neurol Sci; 2013 May; 34(5):769-71. PubMed ID: 23247598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.
    Levraut M; Landes C; Mondot L; Cohen M; Bresch S; Brglez V; Seitz-Polski B; Lebrun-Frenay C
    Front Immunol; 2022; 13():864133. PubMed ID: 35401550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of serum and cerebrospinal fluid ceruloplasmin in multiple sclerosis and other neurologic diseases.
    Becuş T; Popoviciu L; Palade C
    Rev Roum Neurol; 1971; 8(1):3-13. PubMed ID: 5563146
    [No Abstract]   [Full Text] [Related]  

  • 24. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
    Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Khalil M; Renner A; Langkammer C; Enzinger C; Ropele S; Stojakovic T; Scharnagl H; Bachmaier G; Pichler A; Archelos JJ; Fuchs S; Seifert-Held T; Fazekas F
    Mult Scler; 2016 Oct; 22(12):1560-1568. PubMed ID: 26762671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis.
    Dujmovic I; Pekmezovic T; Obrenovic R; Nikolić A; Spasic M; Mostarica Stojkovic M; Drulovic J
    Clin Chem Lab Med; 2009; 47(7):848-53. PubMed ID: 19496733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity.
    Dore-Duffy P; Newman W; Balabanov R; Lisak RP; Mainolfi E; Rothlein R; Peterson M
    Ann Neurol; 1995 Jan; 37(1):55-62. PubMed ID: 7529475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients.
    Filaci G; Contini P; Brenci S; Gazzola P; Lanza L; Scudeletti M; Indiveri F; Mancardi GL; Puppo F
    Hum Immunol; 1997 Apr; 54(1):54-62. PubMed ID: 9154458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity.
    Drulović J; Dujmović I; Mesaros S; Samardzić T; Maksimović D; Stojsavljević N; Lević Z; Mostarica Stojokvić M
    Mult Scler; 2001 Feb; 7(1):19-22. PubMed ID: 11321188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients.
    Drulović J; Mostarica-Stojković M; Lević Z; Stojsavljević N; Pravica V; Mesaros S
    J Neurol Sci; 1997 Apr; 147(2):145-50. PubMed ID: 9106119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques.
    Simone IL; Federico F; Trojano M; Tortorella C; Liguori M; Giannini P; Picciola E; Natile G; Livrea P
    J Neurol Sci; 1996 Dec; 144(1-2):182-90. PubMed ID: 8994122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis.
    Khalil M; Riedlbauer B; Langkammer C; Enzinger C; Ropele S; Stojakovic T; Scharnagl H; Culea V; Petzold A; Teunissen C; Archelos JJ; Fuchs S; Fazekas F
    Mult Scler; 2014 Oct; 20(12):1569-77. PubMed ID: 24777275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker.
    Krametter D; Niederwieser G; Berghold A; Birnbaum G; Strasser-Fuchs S; Hartung HP; Archelos JJ
    Mult Scler; 2001 Feb; 7(1):13-8. PubMed ID: 11321187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
    Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
    J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
    Kastenbauer S; Koedel U; Wick M; Kieseier BC; Hartung HP; Pfister HW
    J Neuroimmunol; 2003 Apr; 137(1-2):210-7. PubMed ID: 12667665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases.
    Rawes JA; Calabrese VP; Khan OA; DeVries GH
    Mult Scler; 1997 Dec; 3(6):363-9. PubMed ID: 9493635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell phenotypic profiles in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients.
    Scolozzi R; Boccafogli A; Tola MR; Vicentini L; Camerani A; Degani D; Granieri E; Caniatti L; Paolino E
    J Neurol Sci; 1992 Mar; 108(1):93-8. PubMed ID: 1352538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.